{
    "nctId": "NCT05697146",
    "briefTitle": "Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France",
    "officialTitle": "Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 482,
    "primaryOutcomeMeasure": "Proportion of patients by initial dose of ribociclib",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPatients who meet all of the following criteria will be included in the RosaLEE study:\n\n1. Adult women aged \u2265 18 years old at inclusion.\n2. Pre-/Peri-/Postmenopausal women with locally advanced or metastatic HR+/HER2- BC.\n3. Prior clinical decision (independent of study participation)to initiate ribociclib + ET treatment according to the marketing authorization.\n4. Patients having given their non-objection to participate in the study.\n5. Patients presenting with medical conditions to be treated with ribociclib + ET according to the summary of product characteristics.\n\nExclusion Criteria:\n\n1. Patients for whom ribociclib + AI in treatment combination has been initiated before inclusion.\n2. Patients for whom ribociclib + fulvestrant in treatment combination has been initiated before inclusion.\n3. Patients for whom AI or fulvestrant in monotherapy has been initiated \\> 28 days before inclusion.\n4. Participation in any clinical study involving investigational therapy except for the Trans-RosaLEE study, conducted by the IPC.\n5. Patient who is pregnant or has expressed desire for pregnancy during Ribociclib treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}